Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Patrick Marban"'
Autor:
Nicholas L. Syn, Andrea Li-Ann Wong, Soo-Chin Lee, Hock-Luen Teoh, James Wei Luen Yip, Raymond CS Seet, Wee Tiong Yeo, William Kristanto, Ping-Chong Bee, LM Poon, Patrick Marban, Tuck Seng Wu, Michael D. Winther, Liam R. Brunham, Richie Soong, Bee-Choo Tai, Boon-Cher Goh
Publikováno v:
BMC Medicine, Vol 16, Iss 1, Pp 1-10 (2018)
Abstract Background Genotype-guided warfarin dosing has been shown in some randomized trials to improve anticoagulation outcomes in individuals of European ancestry, yet its utility in Asian patients remains unresolved. Methods An open-label, non-inf
Externí odkaz:
https://doaj.org/article/087728fcda5943cda118924e863a9094
Autor:
Silvi Kuld, Ramy Saleh, Anna Spreafico, Philippe L. Bedard, Aaron R. Hansen, Olivia Chan, Patrick Marban, Lillian L. Siu, Albiruni Ryan Abdul Razak
Publikováno v:
Clinical Cancer Research. 26:26-26
Background: Early-phase clinical trials are increasingly complex, with “seamless” phase I/II trial designs that include multiple parallel disease and/or biomarker-selected expansion cohorts. Challenges for participating sites in phase 1 (P1) tria
Autor:
Liam R. Brunham, Soo-Chin Lee, Nicholas Syn, James Yip, William Kristanto, Wee Tiong Yeo, Andrea Li Ann Wong, Raymond Cs Seet, Patrick Marban, Michael D. Winther, Richie Soong, Bee Choo Tai, Ping Chong Bee, Li Mei Poon, Boon Cher Goh, Tuck Seng Wu, Hock-Luen Teoh
Publikováno v:
BMC Medicine
BMC Medicine, Vol 16, Iss 1, Pp 1-10 (2018)
BMC Medicine, Vol 16, Iss 1, Pp 1-10 (2018)
Background: Genotype-guided warfarin dosing has been shown in some randomized trials to improve anticoagulation outcomes in individuals of European ancestry, yet its utility in Asian patients remains unresolved. Methods: An open-label, non-inferiorit
Autor:
M.T. Cordero, Lingzhi Wang, Joline Si Jing Lim, M.Q. Yee, David S.P. Tan, Miyuki Yuasa, Soo-Chin Lee, Win Lwin Thuya, Patrick Marban, Brendan Pang, Li Ren Kong, Toshimasa Yamauchi, Boon Cher Goh, Shazib Pervaiz, Y.J. Lee, Richie Soong, Jayshree L. Hirpara, B.R. Asuncion, W.W. Xu, Arvind Kumar Sinha, Takeshi Tsunoda, Masaaki Motoyama, Ross A. Soo, Andrea Li Ann Wong, T.M. Chin
Publikováno v:
Annals of Oncology. 26:998-1005
This phase I study evaluated the safety, pharmacokinetics and pharmacodynamics of OPB-51602, a novel oral small-molecule STAT3 inhibitor, in patients with advanced solid tumors. A tolerable dose was established; gastrointestinal toxicities and periph
Autor:
Boon Cher Goh, Daniel Shao-Weng Tan, Soo-Chin Lee, Masaaki Motoyama, Andrea Li Ann Wong, David Shao Peng Tan, Patrick Marban, Kumi Higuchi, Brendan Pang, Li Ren Kong, Takeshi Tsunoda, Ross A. Soo, Joline Si Jing Lim, Richie Chuan Teck Soong
Publikováno v:
Journal of Clinical Oncology. 32:8028-8028
8028 Background: STAT3, a signal transduction protein of growth factor receptors including EGFR, is constitutively activated in many solid malignancies, leading to tumor angiogenesis, cell prolifer...
Autor:
Soo-Chin Lee, Thuya Win Lwin, Boon Cher Goh, Patrick Marban, Wei Peng Yong, Miyuki Yuasa, Ross A. Soo, Li Ren Kong, Andrea La Wong, Qian Zhu, Tomomi Mikami, Ying Kiat Zee, Benjamin Chuah
Publikováno v:
Journal of Clinical Oncology. 30:3002-3002
3002 Background: STAT3 is constitutively activated by growth signaling pathways in many malignancies; in many cell lines inhibition of STAT3 leads to cell death. OPB51602 is a small molecule inhibitor of STAT3 phosphorylation (Tyr705) and activation.